Soligenix up on pact for blood vessel inflammation treatment

Soligenix

01/05/2023 13:23

** Shares of drug developer Soligenix Inc  SNGX.O  up 5.8%
at $1.63 in premarket trading
    ** Company enters into an exclusive option agreement with
Silk Road Therapeutics
    ** Agreement gives SNGX the right to buy Silk Road's
treatment for mouth and skin ulcers in patients with Behçet's
Disease (BD), a rare disorder causing inflammation in blood
vessels
    ** Terms of the deal are not disclosed
    ** In a mid-stage study, Silk Road's drug PTX was found to
be superior to standard of care in patients with BD
    ** Up to last close, SNGX down 77.3% YTD

 (Reporting by Nandhini Srinivasan in Bengaluru)
 ((nandhini.srinivasan@thomsonreuters.com))